Metformin to Prevent Late Miscarriage and Preterm Delivery in Women With Polycystic Ovary Syndrome
Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
The overall aim of the PregMet 2 Study is to investigate whether metformin prevents late
miscarriages and preterm deliveries in PCOS women treated with metformin from first trimester
of pregnancy to delivery in a large, randomized, controlled, multi-centre trial setting.
The investigators hypothesis is that metformin compared to placebo treatment from the first
trimester to term, reduces the prevalence of late miscarriage (gestational week 13-22) and
preterm birth (gestational week < 37) in PCOS women diagnosed according to Rotterdam 2003
consensus criteria, with singleton pregnancy.
Phase:
N/A
Details
Lead Sponsor:
Norwegian University of Science and Technology
Collaborators:
Alesund Hospital Haukeland University Hospital Karolinska University Hospital Landspitali University Hospital Nordlandssykehuset HF Norrlands universitetssjukhus Umeå St. Olavs Hospital Sykehuset Innlandet HF Sykehuset Telemark The Hospital of Vestfold Uppsala University Hospital Vestre Viken Hospital Trust Vestre Viken Ringerike Sykehus